This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Creager, M. A. Articles by Ryan, T. J. Search for Related Content PubMed PubMed Citation Articles by Creager, M. A. Articles by Ryan, T. J.

Circulation, Vol 64, 483-489, Copyright © 1981 by American Heart Association

ARTICLES

Acute regional circulatory and renal hemodynamic effects of converting- enzyme inhibition in patients with congestive heart failure

MA Creager, JL Halperin, DB Bernard, DP Faxon, CD Melidossian, H Gavras and TJ Ryan

The acute effects of the angiotensin converting-enzyme inhibitor captopril on regional blood flow, renal hemodynamics and sodium excretion were studied in 12 patients with severe congestive heart failure. Converting-enzyme inhibition decreased systemic vascular resistance by 27% and increased cardiac index by 16%. Estimated hepatic blood flow decreased 17%, but renal blood flow increased 60%. The ratio of renal-systemic blood flow increased from 0.10 +/- 0.01 to 0.14 +/- 0.02 (p = 0.031). Although renal plasma flow increased from 202.8 +/- 28.8 to 323.7 +/- 42.7 ml/min (p less than 0.008), the glomerular filtration rate did not change significantly from the mean pretreatment value of 82.1 +/- 12.3 ml/min. The filtration fraction decreased from 41.3 +/- 3.8% to 33.4 +/- 4.5% (p = 0.050), while urinary sodium excretion doubled, from 34.5 +/- 9.6 to 68.2 +/- 19.6 muEq/min. The plasma renin activity increased from 12.6 +/- 5.0 to 29.9 +/- 8.4 ng/ml/hr (p = 0.030) as plasma aldosterone concentration decreased from 30.5 +/- 6.5 to 11.3 4/- 1.2 ng/dl (p = 0.010) and norepinephrine concentrations decreased from 774 +/- 105 to 618 +/- 85 pg/ml (p = 0.020). We conclude that converting-enzyme inhibition reverses renal vasoconstriction in congestive heart failure and redistributes regional blood flow. The natriuresis may be mediated by one or more of the following: improved renal plasma flow, reduction in filtration fraction, suppression of hyperaldosteronism, and lowering of circulatory catecholamine concentrations.

This article has been cited by other articles:

				K. Damman, G. Navis, T. D.J. Smilde, A. A. Voors, W. van der Bij, D. J. van Veldhuisen, and H. L. Hillege Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction Eur J Heart Fail, September 1, 2007; 9(9): 872 - 878. [Abstract] [Full Text] [PDF]

				T. D.J. Smilde, D. J. van Veldhuisen, G. Navis, A. A. Voors, and H. L. Hillege Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction Circulation, October 10, 2006; 114(15): 1572 - 1580. [Abstract] [Full Text] [PDF]

				A. Al-Hesayen and J. D. Parker Impaired Baroreceptor Control of Renal Sympathetic Activity in Human Chronic Heart Failure Circulation, June 15, 2004; 109(23): 2862 - 2865. [Abstract] [Full Text] [PDF]

				A. R. Houghton, M. Harrison, and A. J. Cowley Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy Eur J Heart Fail, December 17, 1999; 1(4): 385 - 393. [Abstract] [Full Text] [PDF]

				D. Annane, E. Bellissant, E. Pussard, R. Asmar, F. Lacombe, E. Lanata, O. Madonna, M. Safar, J.-F. Giudicelli, and P. Gajdos Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema Circulation, September 15, 1996; 94(6): 1316 - 1324. [Abstract] [Full Text]

				M. Kitakaze, T. Minamino, K. Node, K. Komamura, Y. Shinozaki, H. Mori, H. Kosaka, M. Inoue, M. Hori, and T. Kamada Beneficial Effects of Inhibition of Angiotensin-Converting Enzyme on Ischemic Myocardium During Coronary Hypoperfusion in Dogs Circulation, August 15, 1995; 92(4): 950 - 961. [Abstract] [Full Text]

				J. R. Oster and B. J. Materson Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors Arch Intern Med, April 1, 1992; 152(4): 704 - 710. [Abstract] [PDF]

				J. E. Naschitz, D. Yeshurun, and J. Shahar Cardiogenic Hepatorenal Syndrome Angiology, November 1, 1990; 41(11): 893 - 900. [Abstract] [PDF]

				M. A. Munger, S. F. Gardner, and R. C. Jarvis Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331. [Abstract] [PDF]

				M. PACKER, W. H. LEE, N. MEDINA, M. YUSHAK, and P. D. KESSLER Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure Ann Intern Med, March 1, 1987; 106(3): 346 - 354. [Abstract] [PDF]

				M. PACKER, W. H. LEE, N. MEDINA, and M. YUSHAK Influence of Renal Function on the Hemodynamic and Clinical Responses to Long-Term Captopril Therapy in Severe Chronic Heart Failure Ann Intern Med, February 1, 1986; 104(2): 147 - 154. [Abstract] [PDF]

				T. G. Burnakis and H. J. Mioduch Combined Therapy With Captopril and Potassium Supplementation: A Potential for Hyperkalemia Arch Intern Med, December 1, 1984; 144(12): 2371 - 2372. [Abstract] [PDF]

				M. PACKER, N. MEDINA, and M. YUSHAK Correction of Dilutional Hyponatremia in Severe Chronic Heart Failure by Converting-Enzyme Inhibition Ann Intern Med, June 1, 1984; 100(6): 782 - 789. [Abstract] [PDF]